MedPath

Surmodics' Pounce XL Thrombectomy System Receives FDA Clearance

• Surmodics has received FDA 510(k) clearance for its Pounce XL Thrombectomy System, expanding its Pounce platform for peripheral artery thrombus removal. • The Pounce XL is designed for use in 5.5–10mm diameter vessels, including iliac and femoral arteries, addressing a broader range of vessel sizes. • Surmodics plans a limited market release in the first half of 2025, aiming to provide a comprehensive mechanical thrombectomy solution without thrombolytics. • The Pounce platform offers rapid blood flow restoration, potentially reducing the need for follow-up procedures and intensive care admissions.

Surmodics has announced FDA 510(k) clearance for its Pounce XL Thrombectomy System, designed for the non-surgical removal of thrombi and emboli from peripheral arterial vasculature. This expansion of the Pounce platform addresses vessels 5.5–10mm in diameter, including iliac and femoral arteries, offering a solution for a broader range of vessel sizes.
The Pounce XL Thrombectomy System complements Surmodics' existing Pounce Thrombectomy System (3.5–6mm) and Pounce Low Profile (LP) Thrombectomy System (2–4mm), both introduced in recent years. The Pounce platform aims to provide a comprehensive mechanical thrombectomy solution for various peripheral artery sizes.

Addressing Critical Limb Ischemia

Gary Maharaj, president and CEO of Surmodics, emphasized the significance of this clearance: "Securing FDA clearance for Pounce XL is a major step forward in Surmodics’ pursuit of a complete mechanical thrombectomy solution for all peripheral arteries, notably critically ischemic lower extremity vessels." Critical limb ischemia often involves older, organized clots resistant to thrombolysis and aspiration thrombectomy.

Potential Benefits of the Pounce Platform

The Pounce platform allows physicians to rapidly restore blood flow regardless of clot morphology, potentially reducing the need for follow-up procedures and thrombolytic therapy requiring intensive care unit admission. This is particularly relevant for patients with chronic thrombi and emboli in peripheral arteries.

Market Release

Surmodics anticipates a limited market release for the Pounce XL Thrombectomy System in the first half of 2025, with full commercialization planned after the initial release phase.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Grants 510(k) Clearance to RELIEF Stent for Vesicoureteral Reflux

The FDA has approved the RELIEF ureteral stent for preventing vesicoureteral reflux, marking the first such approval in the U.S. The stent, developed by The Ureteral Stent Company, aims to address the significant side effects associated with current stents, such as reflux and bladder spasms, through its unique design.

Simpson Interventions' Acolyte Catheter System Receives IDE Approval, Shadow Catheter Cleared by FDA

Simpson Interventions' Acolyte System, designed for coronary chronic total occlusion revascularization, has received FDA Investigational Device Exemption (IDE).
The FDA also granted 510(k) clearance to Simpson Interventions' Shadow Catheter, facilitating its commercialization for interventional cardiology procedures.

AngioDynamics' NanoKnife System Receives FDA Clearance for Prostate Tissue Ablation

AngioDynamics has received FDA clearance for its NanoKnife System for prostate tissue ablation, marking a significant advancement in minimally invasive cancer treatment.
The PRESERVE clinical study demonstrated that 84% of men were free from clinically significant prostate cancer 12 months post-procedure using the NanoKnife System.

Centerline Biomedical's IOPS Guidewire Handle Receives FDA 510(k) Clearance

Centerline Biomedical's IOPS Guidewire Handle, a second-generation device, has received FDA 510(k) clearance, enhancing its IOPS technology portfolio.
The IOPS Guidewire Handle, used with a sensorized guidewire and viewpoint catheter, supports real-time 3D navigation of vasculature.

Nanox's ARC Imaging System Receives FDA Clearance for Expanded Use

Nanox's ARC imaging system secures FDA 510(k) clearance for general use, including pulmonary, intra-abdominal, and paranasal sinus indications, expanding its market potential.
The Nanox.ARC system utilizes digital X-ray technology with cold cathode tomosynthesis, providing enhanced 3D visualization compared to traditional 2D X-rays.

Sonoma Pharmaceuticals Gains FDA Clearance for Enhanced Microcyn Hydrogel

Sonoma Pharmaceuticals has received FDA 510(k) clearance for its Microcyn-based hydrogel, enhancing its wound care applications.
The new clearance includes improved biocompatibility and extends the product's shelf life to 24 months for 50mL bottles.

Momentis Surgical's Anovo Robotic Platform Gains FDA Clearance for Enhanced Capabilities

Momentis Surgical received FDA 510(k) clearance for its second-generation Anovo robotic surgical platform, enhancing surgeon experience and ease of use.
The updated Anovo platform introduces haptic feedback and dual-mode articulation, allowing operation in both retroflexion and anteflexion from a single incision.

L&K Biomed's BluEX Lumbar Expandable Cage System Receives FDA Approval

L&K Biomed secured FDA 510(k) clearance for its BluEX Lumbar Expandable Cage System, designed for enhanced bone integration and versatile surgical approaches.
The BluEX system features six cage designs adaptable for anterior, posterior, lateral, ATP, and endoscopic lumbar approaches, offering surgeons greater flexibility.

FDA Approves RoxyBond, an Abuse-Deterrent Oxycodone for Severe Pain

The FDA has approved RoxyBond (oxycodone hydrochloride), an immediate-release tablet with abuse-deterrent properties, for managing severe pain requiring opioid analgesics.
RoxyBond utilizes SentryBond technology to resist physical and chemical manipulation, reducing the potential for misuse via crushing, dissolving, or injection.

Elixir Medical's DynamX BTK System Receives FDA Breakthrough Device Designation for Chronic Limb-Threatening Ischemia

Elixir Medical's DynamX BTK System receives FDA Breakthrough Device Designation for treating below-the-knee arterial disease in chronic limb-threatening ischemia (CLTI) patients.
The DynamX Bioadaptor platform aims to restore vessel function by providing dynamic support during healing and maintaining an open lumen in affected vessels.

Reference News

[1]
Surmodics receives FDA 510(k) clearance for Pounce XL thrombectomy system
vascularnews.com · Oct 2, 2024

Surmodics received FDA 510(k) clearance for its Pounce XL thrombectomy system, indicated for non-surgical removal of thr...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy